Risk Intelligence
Working capital pressure from inventory buildup
View Risks →Fineotex Chemical delivered a stellar Q4 FY26, with revenue surging 162% YoY to ₹314 crore and PAT jumping 118% to ₹44 crore, driven by the December 2025 acquisition of Crude Chem Technologies (CCT) and strong organic textile chemical growth.
✓ Verified against BSE filing
Fineotex Chemical delivered a stellar Q4 FY26, with revenue surging 162% YoY to ₹314 crore and PAT jumping 118% to ₹44 crore, driven by the December 2025 acquisition of Crude Chem Technologies (CCT) and strong organic textile chemical growth. The US oilfield chemicals business contributed ~₹165 crore in Q4, with management confident of scaling to $200 million revenue by FY28 (revised from 2030). Consolidated EBITDA margin stood at 14%, with a target of 18-20% in the near term. The company is doubling CCT's manufacturing capacity and has already deployed $7 million in capex. Textile volumes grew 15% YoY, supported by improving export demand. Risks include working capital pressure (79 days) and global logistics disruptions, though management views these as manageable. The strong balance sheet (₹300+ crore cash) supports further inorganic opportunities.
फाइनोटेक्स केमिकल ने चौथी तिमाही में शानदार प्रदर्शन किया। कंपनी की आय पिछले साल की तुलना में 162% बढ़कर ₹314 करोड़ हो गई, और मुनाफा 118% बढ़कर ₹44 करोड़ पहुंच गया। यह वृद्धि दिसंबर 2025 में क्रूड केम टेक्नोलॉजीज (CCT) को खरीदने और टेक्सटाइल केमिकल के मजबूत कारोबार से हुई। अमेरिकी तेल क्षेत्र के केमिकल कारोबार ने चौथी तिमाही में ₹165 करोड़ का योगदान दिया। कंपनी का लक्ष्य वित्त वर्ष 2028 तक $200 मिलियन का राजस्व हासिल करना है। EBITDA मार्जिन 14% रहा, जिसे जल्द ही 18-20% तक ले जाने की योजना है। कंपनी CCT की उत्पादन क्षमता दोगुनी कर रही है और $7 मिलियन का निवेश कर चुकी है। टेक्सटाइल की बिक्री 15% बढ़ी। जोखिमों में कार्यशील पूंजी का दबाव (79 दिन) और वैश्विक आपूर्ति में रुकावट शामिल है, लेकिन कंपनी के पास ₹300 करोड़ से अधिक नकदी है, जो आगे और अवसरों में मदद करेगी।
Working capital pressure from inventory buildup
View Risks →Full transcript text is available on this route.
Read Transcript →Crude Chem contributed ~₹165 crore in Q4 FY26, forming the bulk of the incremental revenue.
International revenue share rose to 70% in Q4 FY26 from ~50% in Q4 FY25, reflecting global diversification.
Return on invested capital remained healthy at 31%, indicating efficient capital allocation.
Textile specialty chemical volumes grew 15% YoY in Q4, driven by improving export demand.
Management revised the CCT revenue target from 2030 to FY28, with Q4 FY26 as the baseline run-rate of ~$90-100 million.
Management expects blended EBITDA margins to improve to 18-20% in the near term, possibly within FY27.
CCT's manufacturing capacity is being doubled with $7 million capex already deployed; new machines being installed.
Agreement to acquire an additional 25% stake from founders by January 2028, increasing ownership to ~79-80%.
Management expects consolidated revenue to exceed ₹1,000 crore in the next financial year, driven by CCT full-year contribution and textile recovery.
Oil & gas segment (including CCT) is expected to account for 45-50% of total revenue going forward.
CCT's EBITDA margins, historically around 7-8%, are expected to improve to double digits due to capital infusion and better procurement.
Capital expenditure for CCT expansion and other projects is expected to be around ₹70-80 crore (less than $10 million) over the next 1.5-2 years.
Working capital cycle increased to 79 days (85 days for CCT) due to global logistics disruptions and raw material shortages, which could strain cash flows.
Management acknowledged container shortages and freight cost increases, which may impact margins if not fully passed through.
Rapid capacity expansion and technology transfer to CCT may face operational hiccups, though management is confident.
CCT's growth is tied to US oil and gas activity; any downturn in drilling or regulatory changes could impact demand.
CCT was consolidated for only 15 days in Q3; achieving double-digit margins may take longer than expected due to integration complexities.
Management provided discounts to textile customers during the tariff uncertainty and plans to roll them back from March 2026, which could impact customer retention.
Domestic revenue remained flat YoY at ~₹95.6 crore, indicating limited organic growth in the home market despite new capacity.
Textile recovery hinges on favorable US tariff resolution; any reversal or delay could impact expected order book improvement.
Management revised the CCT revenue target from 2030 to FY28, with Q4 FY26 as the baseline run-rate of ~$90-100 million.
Working capital cycle increased to 79 days (85 days for CCT) due to global logistics disruptions and raw material shortages, which could strain cas...
View Risks →